Tuberculin skin test size and risk of tuberculosis development: A large population-based study in contacts

International Journal of Tuberculosis and Lung Disease

Volumn 11, Issue 9, 2007, Pages 1014-1020

  Morán Mendoza, Onofre ^a   Marion, S A ^b   Elwood, K ^b   Patrick, D M ^b   FitzGerald, J M ^b  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Latent tuberculosis infection; Tuberculin skin test; Tuberculosis risk

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL TRANSMISSION; CANADA; CHILD; CONTROLLED STUDY; DATA BASE; FEMALE; GROUPS BY AGE; HOUSEHOLD; HUMAN; IMMUNE DEFICIENCY; INFANT; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NEWBORN; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TUBERCULIN TEST; TUBERCULOSIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BRITISH COLUMBIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONTACT TRACING; FAMILY CHARACTERISTICS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; INFANT, NEWBORN; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 34548755058     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. MMWR 1999; 48: 1-13.
2. Small P M, Fujiwara P I. Management of tuberculosis in the United States. N Engl J Med 2001; 345: 189-200.
3. Bates B H, Ayvazian L F. The American Lung Association Conference on Re-Establishing Control of Tuberculosis in the United States. Am J Respir Crit Care Med 1996; 154: 251-262.
4. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005; 172: 1169-1227.
5. American Thoracic Society and the Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-S247.
6. Canadian Lung Association, Canadian Thoracic Society, Tuberculosis Prevention and Control, et al. Canadian tuberculosis standards. 5th ed. Ottawa, Canada: Canadian Lung Association and Government of Canada, 2000.
7. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161: 1376-1395.
8. British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000. Thorax 2000; 55: 887-901.
9. American Thoracic Society. Preventive treatment in tuberculosis: a statement by the Committee on Therapy. Am Rev Respir Dis 1965; 91: 297-298.
10. Canadian Tuberculosis and Respiratory Disease Association. Canadian tuberculosis standards. Ottawa, Canada: 1972.
11. Hosmer D W, Lemeshow S. Assessment of model adequacy. In: Hosmer D W, Lemeshow S, eds. Applied survival analysis. New York, NY, USA: John Wiley & Sons, 1999: p 196-240.
12. Comstock G W, Ferebee S H, Hammcs I. M. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967; 95: 935-943.
13. Ferebee S H. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 1970; 17: 28-106.
14. Comstock G W, Palmer C E. Long term results of BCG vaccination in the southern United States. Am Rev Respir Dis 1966; 93: 171-183.
15. Horwitz O, Wilbek E, Erickson P A. Epidemiological basis of tuberculosis eradication. 10. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull World Health Organ 1969; 41: 95-113.
16. Comstock G W, Livesay V T, Woolpert S F. Evaluation of BCG vaccination among Puerto Rican children. Am J Public Health 1974; 64: 283-291.
17. Comstock G W, Woolpert S F, Livesay V T. Tuberculosis studies in Muscogee County, Georgia. Twenty-year evaluation of a community trial of BCG vaccination. Public Health Rep 1976; 91: 276-280.
18. Tuberculosis Prevention Trial. Trial of BCG vaccines in south India for tuberculosis prevention. Indian J Med Res 1979; 70: 349-363.
19. Fine P E, Sterne J A, Ponnighaus J M, et al. Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet 1994; 344: 1245-1249.
20. Comstock G W, Edwards L B, Livesay V T. Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis 1974; 110: 572-580.
21. Chee C B, Soh C H, Boudville I C, et al. Interpretation of the tuberculin skin test in Mycobacterium bovis BCG-vaccinated Singaporean schoolchildren. Am J Respir Crit Care Med 2001; 164: 958-961.
22. MacIntyre C R, Plant A J. Preventability of incident cases of tuberculosis in recently exposed contacts. Int J Tuberc Lung Dis 1998; 2: 56-61.
23. Radhakrishna S, Frieden T R, Subramani R. Association of initial tuberculin sensitivity, age and sex with the incidence of tuberculosis in South India: a 15-year follow-up. Int J Tuberc Lung Dis 2003; 7: 1083-1091.
24. MacIntyre C R, Plant A J. Longitudinal incidence of tuberculosis in South-East Asian refugees after re-settlement. Int J Tuberc Lung Dis 1999; 3: 287-293.
25. Marks G B, Bai J, Simpson S E, et al. Incidence of tuberculosis among a cohort of tuberculin-positive refugees in Australia: reappraising the estimates of risk. Am J Respir Crit Care Med 2000; 162: 1851-1854.
26. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005; 172: 1169-1227.
27. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564.
28. Hennekens C H, Buring J E. Epidemiology in medicine. Toronto, Canada: Little, Brown and Company, 1987.
29. Mazurek G H, Villarino M E. Guidelines for using the Quanti-FERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52: 15-18.
30. Meier T, Eulenbruch H P, Wrighton-Smith P, et al. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis 2005; 24: 529-536.